Praxis Precision Medicines (NASDAQ:PRAX) Issues Quarterly Earnings Results

Praxis Precision Medicines (NASDAQ:PRAX) announced its quarterly earnings data on Thursday. The company reported ($2.87) EPS for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines’ conference call:

• Ulixacaltamide and relutrigine remain on track for potential FDA decisions, with target dates around January 2027 and December 27, 2026, respectively. Praxis said neither program is expected to require an advisory committee meeting, and FDA mid-cycle reviews identified no significant efficacy issues.
• Praxis has substantially advanced its commercial preparations, including hiring and training the relutrigine field team, building the ulixacaltamide sales force, establishing distribution and supply networks, and developing patient-support programs. Management expects to be launch-ready ahead of the anticipated approvals.
• Enrollment in the EMERALD broad developmental and epileptic encephalopathy study exceeded its target at approximately 200 patients across more than 50 genetic etiologies. If positive, the company expects the data could support a supplemental filing for relutrigine in 2027.
• Vormatrigine’s POWER1 study failed its primary endpoint in highly refractory focal-onset seizures, although it met a key responder secondary endpoint. Praxis plans to amend POWER2 and POWER3 based on learnings about dose, treatment duration, and patient selection, with both studies expected to restart by the fourth quarter.
• Second-quarter operating expenses increased to $96.9 million and operating cash usage rose to $78 million, reflecting greater development and commercial spending. Praxis ended the quarter with $1.4 billion in cash and marketable securities, which management believes funds operations into 2028.

Praxis Precision Medicines Price Performance

Shares of NASDAQ PRAX traded down $9.40 during trading on Friday, hitting $360.76. The stock had a trading volume of 454,828 shares, compared to its average volume of 476,464. The firm has a fifty day moving average of $303.77 and a two-hundred day moving average of $315.47. The company has a market capitalization of $10.06 billion, a PE ratio of -26.98 and a beta of 2.78. Praxis Precision Medicines has a 12 month low of $37.19 and a 12 month high of $382.54.

Analyst Upgrades and Downgrades

PRAX has been the topic of a number of recent research reports. Wedbush cut their target price on Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a report on Tuesday, June 2nd. Piper Sandler restated an “overweight” rating on shares of Praxis Precision Medicines in a research note on Monday, July 13th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $374.00 price objective (down from $420.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. The Goldman Sachs Group started coverage on shares of Praxis Precision Medicines in a research note on Monday, July 13th. They issued a “buy” rating and a $447.00 price objective on the stock. Finally, HC Wainwright reduced their price objective on shares of Praxis Precision Medicines from $1,245.00 to $1,201.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $573.05.

Insider Buying and Selling at Praxis Precision Medicines

In related news, Director Jill Desimone sold 11,600 shares of the business’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the transaction, the director directly owned 2,337 shares in the company, valued at approximately $727,554.84. The trade was a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of PRAX. Tower Research Capital LLC TRC increased its position in shares of Praxis Precision Medicines by 24.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock valued at $77,000 after acquiring an additional 359 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Praxis Precision Medicines in the fourth quarter worth $163,000. Norges Bank bought a new position in Praxis Precision Medicines in the 2nd quarter valued at $210,000. Commonwealth Equity Services LLC bought a new position in Praxis Precision Medicines in the 4th quarter valued at $220,000. Finally, O Shaughnessy Asset Management LLC purchased a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at $226,000. Hedge funds and other institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.